Thomas R. Staab II, Senior Vice President and CFO at BIOCRYST PHARMACEUTICALS INC (BCRX), sold 3,250 shares at $9.20 ($30K) on 2017-03-20, disclosed to the SEC on 2017-03-22.
Scheduled sale ($30k) by Senior Vice President and CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BCRX | SELL | 2019-05-16 | $92K | — | Filing → |
| BCRX | SELL | 2019-05-13 | $224K | — | Filing → |
| BCRX | SELL | 2019-05-06 | $126K | — | Filing → |